Brokerages expect that Integer Holdings Corp (NYSE:ITGR) will post sales of $319.60 million for the current quarter, Zacks reports. Two analysts have made estimates for Integer’s earnings, with estimates ranging from $315.10 million to $324.10 million. Integer reported sales of $314.46 million in the same quarter last year, which would suggest a positive year over year growth rate of 1.6%. The business is expected to report its next quarterly earnings results before the market opens on Thursday, August 1st.
On average, analysts expect that Integer will report full-year sales of $1.28 billion for the current year. For the next fiscal year, analysts expect that the firm will post sales of $1.34 billion. Zacks Investment Research’s sales averages are an average based on a survey of analysts that that provide coverage for Integer.
Integer (NYSE:ITGR) last announced its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.00 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.80 by $0.20. Integer had a net margin of 14.67% and a return on equity of 13.37%. The firm had revenue of $314.70 million for the quarter, compared to analyst estimates of $302.29 million. During the same quarter last year, the business earned $0.61 earnings per share. Integer’s revenue was up 7.6% compared to the same quarter last year.
ITGR has been the topic of a number of analyst reports. ValuEngine lowered shares of Virtu Financial from a “hold” rating to a “sell” rating in a research report on Tuesday, June 18th. Argus raised their target price on shares of Aqua America from $2.00 to $43.00 in a research report on Wednesday, June 5th. They noted that the move was a valuation call. Finally, Zacks Investment Research downgraded shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Wednesday, April 24th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $74.66.
In related news, Director James F. Hinrichs purchased 3,750 shares of the business’s stock in a transaction on Thursday, May 23rd. The shares were bought at an average price of $68.47 per share, with a total value of $256,762.50. Following the completion of the purchase, the director now directly owns 6,549 shares in the company, valued at approximately $448,410.03. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 2.24% of the company’s stock.
A number of large investors have recently bought and sold shares of the business. Optimum Investment Advisors purchased a new position in shares of Integer in the 1st quarter valued at $30,000. Robeco Institutional Asset Management B.V. purchased a new position in shares of Integer in the 1st quarter valued at $40,000. Financial Gravity Wealth Inc. purchased a new position in shares of Integer in the 1st quarter valued at $45,000. PNC Financial Services Group Inc. raised its stake in shares of Integer by 15.8% in the 4th quarter. PNC Financial Services Group Inc. now owns 1,065 shares of the medical equipment provider’s stock valued at $81,000 after acquiring an additional 145 shares during the period. Finally, Pearl River Capital LLC purchased a new position in shares of Integer in the 1st quarter valued at $120,000. 96.00% of the stock is currently owned by institutional investors.
NYSE ITGR traded up $0.21 during mid-day trading on Friday, reaching $82.33. 141,180 shares of the stock were exchanged, compared to its average volume of 240,957. Integer has a 1-year low of $67.72 and a 1-year high of $92.61. The firm’s fifty day simple moving average is $78.14. The firm has a market capitalization of $2.68 billion, a PE ratio of 21.67 and a beta of 0.95. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.55 and a quick ratio of 1.49.
Integer Company Profile
Integer Holdings Corporation operates as a medical device outsource manufacturer worldwide. It operates in two segments, Medical and Non-Medical. The company offers products for vascular, cardiac surgery, and structural heart diseases; peripheral vascular, neurovascular, urology, and oncology products; and electrophysiology, infusion therapy, and hemodialysis products.
Featured Article: What is the Fibonacci sequence?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.